SapC-DOPS Nanovesicles With Gemcitabine for PS-Targeted PDAC Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Pancreatic ductal adenocarcinoma (PDAC) has a high mortality rate and lacks effective therapeutic approaches, with current treatments like gemcitabine only prolonging survival by a few months, and there is a need for novel methods that target high surface phosphatidylserine (PS) expression in cancer cells.
Innovation Solution
Administering a combination of SapC-DOPS, a biologic anticancer agent targeting high PS, with gemcitabine, which selectively targets different phases of the cell cycle, enhancing treatment efficacy by sensitizing cells to SapC-DOPS through increased PS expression induced by gemcitabine.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If gemcitabine is used as standard chemotherapy treatment for PDAC, then survival is prolonged by several months, but treatment efficacy remains limited and mortality rate stays high at 94%
Solution Approach 1:
The patent combines gemcitabine chemotherapy with SapC-DOPS nanovesicles that target phosphatidylserine on cancer cell surfaces. This merging of conventional chemotherapy with targeted biologic therapy creates a synergistic effect that overcomes the limited efficacy of gemcitabine alone, achieving complete tumor eradication in preclinical models while extending survival.
Solution Approach 2:
SapC-DOPS acts as an intermediary that enhances the effectiveness of gemcitabine by selectively targeting and disrupting cancer cell membranes through phosphatidylserine binding. This intermediary mechanism sensitizes tumor cells to gemcitabine-induced apoptosis, thereby improving overall treatment efficacy without increasing gemcitabine dosage.
2Object-affected harmful factors
If SapC-DOPS targets high surface phosphatidylserine on cancer cells, then selective tumor cell killing is achieved, but combination with standard chemotherapy is needed to maximize efficacy
Solution Approach 1:
The patent merges the selective targeting capability of SapC-DOPS with the cytotoxic mechanism of gemcitabine. SapC-DOPS provides selective binding to phosphatidylserine-exposing cancer cells, while gemcitabine delivers potent anti-proliferative and pro-apoptotic effects, together achieving both high selectivity and high efficacy.
Solution Approach 2:
The combination therapy induces changes in phosphatidylserine exposure parameters on cancer cell surfaces, creating a feedback loop where initial SapC-DOPS binding and gemcitabine treatment further increase PS exposure, thereby enhancing subsequent SapC-DOPS binding and creating a self-amplifying therapeutic effect that maximizes anti-tumor efficacy.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The combination of SapC-DOPS and gemcitabine significantly enhances anti-tumor effects, selectively targeting and killing pancreatic cancer cells, reducing tumor growth, and prolonging survival in both in vitro and in vivo models.
Implementation Method 1
SapC binds PS on the surface of cells with high affinity and once inside the cell can bind membrane PS and activate lysosomal enzymes
Implementation Method 2
SapC binds PS on the surface of cells with high affinity and once inside the cell can bind membrane PS and activate lysosomal enzymes, leading to ceramide production and subsequent apoptotic cancer cell death
Implementation Method 3
an increase in surface PS is a common consequence of cytotoxic drug exposure, suggesting that standard chemotherapy treatments for PDAC (e.g. GEM) and other cancers may potentiate the anti-tumor actions of SapC-DOPS as SapC-DOPS more readily kills cells with high surface PS
Data Source
AI summary
The present disclosure concerns methods for treating pancreatic cancer cells with a combination of gemcitabine (GEM) and SapC-DOPS. In some aspects, GEM treatment preferentially targets G1 phase cells which are low in surface phosphatidylserine (PS), resulting in an increased median surface PS level of PDAC cells. Inversely, SapC-DOPS targets high surface PS cells which are predominantly in the G2/M phase. In other aspects, a combination therapy on tumors in vivo with SapC-DOPS and GEM or Abraxane® (Abr)/GEM is demonstrated to significantly inhibit tumor growth and increases survival.